Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 3.89 INR
Change Today 0.00 / 0.00%
Volume 0.0
ABT On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:00 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

abl bio-technologies ltd (ABT) Snapshot

Open
4.00
Previous Close
4.09
Day High
4.01
Day Low
3.89
52 Week High
05/19/14 - 6.30
52 Week Low
12/17/14 - 1.80
Market Cap
31.9M
Average Volume 10 Days
9.1K
EPS TTM
-0.18
Shares Outstanding
8.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ABL BIO-TECHNOLOGIES LTD (ABT)

Related News

No related news articles were found.

abl bio-technologies ltd (ABT) Related Businessweek News

No Related Businessweek News Found

abl bio-technologies ltd (ABT) Details

ABL Biotechnologies Limited engages in the discovery and collection of microbes, establishment of compound libraries, and discovery of drug and nutrition targets. It operates through three segments: Formulation, Research and Development, and The DHA project. The company is also involved in conducting research and converting the strains/compounds collected into deliverable active pharmaceutical products. It offers softgel capsules. ABL Biotechnologies Limited was incorporated in 1992 and is based in Chennai, India.

Founded in 1992

abl bio-technologies ltd (ABT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

abl bio-technologies ltd (ABT) Key Developments

ABL Bio-Technologies Ltd. Announces Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

ABL Bio-Technologies Ltd. announced unaudited standalone and consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the quarter on standalone and consolidated basis, the company reported total net income from operations of INR 0.016 million against INR 0.016 million a year ago. Loss from operations before other income, fiancé costs and exceptional items was INR 0.399 million against INR 0.366 million a year ago. Loss from ordinary activities before tax was INR 0.399 million against INR 0.366 million a year ago. Net profit was INR 0.399 million against INR 0.366 million a year ago. Loss per basic and diluted share was INR 0.05 against INR 0.04 a year ago. For the nine months on standalone and consolidated basis, the company reported total net income from operations of INR 0.048 million against INR 0.048 million a year ago. Loss from operations before other income, fiancé costs and exceptional items was INR 1.215 million against INR 1.084 million a year ago. Loss from ordinary activities before tax was INR 1.215 million against INR 1.084 million a year ago. Net profit was INR 1.215 million against INR 1.084 million a year ago. Loss per diluted share was INR 0.15 against INR 0.05 a year ago.

ABL Bio-Technologies Ltd., Board Meeting, Feb 11, 2015

ABL Bio-Technologies Ltd., Board Meeting, Feb 11, 2015. Agenda: To consider unaudited standalone and consolidated earnings results for the third quarter and nine months ended December 31, 2014.

Abl Bio-Technologies Ltd. Announces Unaudited Consolidated and Standalone Financial Results for the Second Quarter and Six Months Ended Sept. 30, 2014

ABL Bio-Technologies Ltd. announced unaudited consolidated and standalone financial results for the second quarter and six months ended Sept. 30, 2014. For the quarter, the parent company reported loss from operations before other income, finance costs & exceptional items of INR 0.4 million against INR 0.34 million for the same period of last year. Loss from ordinary activities before tax was INR 0.4 million against INR 0.34 million for the same period of last year. Net loss for the period was INR 0.4 million or INR 0.05 per basic and diluted share against INR 0.34 million or INR 0.04 per basic and diluted share for the same period of last year. Total income from operations were INR 0.016 million against INR 0.016 million for the same period of last year. For the nine months, the parent company reported loss from operations before other income, finance costs & exceptional items of INR 0.816 million against INR 0.718 million for the same period of last year. Loss from ordinary activities before tax was INR 0.816 million against INR 0.718 million for the same period of last year. Net loss for the period was INR 0.816 million or INR 0.1 per basic and diluted share against INR 0.718 million or INR 0.05 per basic and diluted share for the same period of last year. Total income from operations were INR 0.032 million against INR 0.032 million for the same period of last year. For the quarter, the group reported loss from operations before other income, finance costs & exceptional items of INR 0.4 million against INR 0.34 million for the same period of last year. Loss from ordinary activities before tax was INR 0.4 million against INR 0.34 million for the same period of last year. Net loss for the period was INR 0.4 million or INR 0.05 per basic and diluted share against INR 0.34 million or INR 0.04 per basic and diluted share for the same period of last year. Total income from operations were INR 0.016 million against INR 0.016 million for the same period of last year. For the nine months, the group reported loss from operations before other income, finance costs & exceptional items of INR 0.813 million against INR 0.718 million for the same period of last year. Loss from ordinary activities before tax was INR 0.813 million against INR 0.718 million for the same period of last year. Net loss for the period was INR 0.813 million or INR 0.1 per basic and diluted share against INR 0.718 million or INR 0.05 per basic and diluted share for the same period of last year. Total income from operations were INR 0.032 million against INR 0.032 million for the same period of last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT:IN 3.89 INR 0.00

ABT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ABT.
View Industry Companies
 

Industry Analysis

ABT

Industry Average

Valuation ABT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABL BIO-TECHNOLOGIES LTD, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.